References
- Grillo-Lopez AJ. The ODAC Chronicles - Part I: My First ODAC Experience. Expert Rev. Anticancer Ther. 4(5), 579–582 (2004).
- Rothmann ML, Li N, Chen G, Chi GYH, Temple R, Tsou HH. Design and analysis of non-inferiority mortality trials in oncology. Stat. Med. 22,239–264 (2003).
- Grillo-LOpez AJ. Cancer therapies crisis in the USA. Expert Rev Anticancer Ther. 3(5), 579–582 (2003).
Websites
- Transcript of ODAC meeting: Genasense, 349 (2004) www.fda.goviohrmsidockets/ac/04/ transcripts/4037T1.pdf (Accessed November 2004)
- Transcript of ODAC meeting: Genasense, 353 (2004) www.fda.goviohrmsidocketsiac/04/ transcripts/4037T1.pdf (Accessed November 2004)
- Transcript of ODAC meeting: Genasense, 76–86 (2004) www.fda.goviohrmsidocketsiac/04/ transcripts/4037T1.pdf (Accessed November 2004)
- Briefing material for ODAC meeting: Genasense, 1–62 (2004) www.fda.goviohrmsidocketsiac/04/ briefing/4037B1_02_FDA-Genasense.pdf (Accessed November 2004)
- Transcript of ODAC meeting: Genasense, 176–201 (2004) www.fda.goviohrmsidocketsiac/04/ transcripts/4037T1.pdf (Accessed November 2004)
- ODAC statistical review and evaluation: clinical studies: Alimta. 1–41 (2004). www.fda.goviohrmsidocketsiac/04/briefing/ 2004-4060B1_02_C-FDA-statistical.pdf (Accessed November 2004)
- ODAC clinical review and evaluation: Alimta (2004). www.fda.goviohrmsidocketsiac/04/briefing/ 2004-4060B1_02_B-FDA-clinical.pdf (Accessed November 2004)